Abstract
Cancer is one of the highest causes of morbidity and mortality worldwide. Traditional chemotherapeutics are associated with toxic side effects due to a lack of specificity for cancer cells. A new and rapidly expanding class of drugs known as targeted therapeutics are being developed that have high therapeutic potential with less severe side effects in comparison to conventional chemotherapeutics. Targeted therapeutics are aimed at defects found in cancer cells that are not present in the highly-proliferative cells of normal tissues. These defects include dys regulated oncogenes and DNA repair defects that cause cells to rely heavily on the DNA damage response (DDR) and checkpoint signaling. This association indicates that the DDR may include promising targets for targeted therapeutics. Examples of such therapeutics currently under investigation and in clinical use are described here, including inhibitors of PARP, DNA-PKcs and the ATR-CHK1 signaling pathway. Targeted therapeutics not only offer the promise of killing cancers with reduced side effects, but are well suited to use in combination with other therapeutics to increase efficacy and kill cancers before drug-resistance can occur.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
American Cancer Society 2014 Second cancers in adults. 12/11/14 [cited 2016 11/14/16]; Available from: http://www.cancer.org/acs/groups/cid/documents/webcontent/002043-pdf.pdf
An X et al (2010) BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res 34(10):1255–1268
Andreassen PR, D'Andrea AD, Taniguchi T (2004) ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev 18(16):1958–1963
Anglian Breast Cancer Study Group (2000) Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83(10):1301–1308
Atherton-Fessler S et al (1994) Cell cycle regulation of the p34cdc2 inhibitory kinases. Mol Biol Cell 5(9):989–1001
Audeh MW et al (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376(9737):245–251
Bartkova J et al (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434(7035):864–870
Bartkova J et al (2006) Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444(7119):633–637
Baumann P, West SC (1998) Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci 23(7):247–251
Beck H et al (2012) Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption. Mol Cell Biol 32(20):4226–4236
Bester AC et al (2011) Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell 145(3):435–446
Bignell GR et al (2010) Signatures of mutation and selection in the cancer genome. Nature 463(7283):893–898
Booher RN, Holman PS, Fattaey A (1997) Human Myt1 is a cell cycle-regulated kinase that inhibits Cdc2 but not Cdk2 activity. J Biol Chem 272(35):22300–22306
Bouwman P et al (2010) 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 17(6):688–695
Boyer AS et al (2013) The human specialized DNA polymerases and non-B DNA: vital relationships to preserve genome integrity. J Mol Biol 425(23):4767–4781
Branzei D, Foiani M (2008) Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol 9(4):297–308
Branzei D, Foiani M (2010) Maintaining genome stability at the replication fork. Nat Rev Mol Cell Biol 11(3):208–219
Brown EJ, Baltimore D (2000) ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev 14(4):397–402
Brown EJ, Baltimore D (2003) Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. Genes Dev 17(5):615–628
Bryant HE et al (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434(7035):913–917
Bunting SF et al (2010) 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141(2):243–254
Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609–615
Casper AM et al (2002) ATR regulates fragile site stability. Cell 111(6):779–789
Chang HHY et al (2017) Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat Rev Mol Cell Biol 18(8):495–506
Chanoux RA et al (2009) ATR and H2AX cooperate in maintaining genome stability under replication stress. J Biol Chem 284(9):5994–6003
Chen MS, Ryan CE, Piwnica-Worms H (2003) Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14-3-3 binding. Mol Cell Biol 23(21):7488–7497
Chen L et al (2008) Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair. J Biol Chem 283(12):7713–7720
Chiarugi A (2012) A snapshot of chemoresistance to PARP inhibitors. Trends Pharmacol Sci 33(1):42–48
Cortez D (2015) Preventing replication fork collapse to maintain genome integrity. DNA Repair (Amst) 32:149–157
Couch FB et al (2013) ATR phosphorylates SMARCAL1 to prevent replication fork collapse. Genes Dev 27(14):1610–1623
Couedel C et al (2004) Collaboration of homologous recombination and nonhomologous end-joining factors for the survival and integrity of mice and cells. Genes Dev 18(11):1293–1304
Curtis RE, Freedman DM, Ron E, LAG R, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr (2006) New malignancies among cancer survivors: SEER cancer registries, 1973–2000. NIH: National Cancer Institute, Bethesda, MD
Denko NC et al (1994) The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. Proc Natl Acad Sci U S A 91(11):5124–5128
Di Micco R et al (2006) Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444(7119):638–642
Dillon LW, Burrow AA, Wang YH (2010) DNA instability at chromosomal fragile sites in cancer. Curr Genomics 11(5):326–337
Dominguez-Kelly R et al (2011) Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease. J Cell Biol 194(4):567–579
Duda H et al (2016) A mechanism for controlled breakage of under-replicated chromosomes during mitosis. Dev Cell 39(6):740–755
Falck J et al (2001) The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410(6830):842–847
Farmer H et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917–921
Feijoo C et al (2001) Activation of mammalian Chk1 during DNA replication arrest: a role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing. J Cell Biol 154(5):913–923
Felsher DW, Bishop JM (1999) Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci U S A 96(7):3940–3944
Fernandez-Medarde A, Santos E (2011) Ras in cancer and developmental diseases. Genes Cancer 2(3):344–358
Ferrao PT et al (2012) Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells. Oncogene 31(13):1661–1672
Flaherty KT et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363(9):809–819
Fokas E et al (2012) Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis 3:e441
Gilad O et al (2010) Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner. Cancer Res 70(23):9693–9702
Glover TW et al (1984) DNA polymerase alpha inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum Genet 67(2):136–142
Gong Z et al (2010) BACH1/FANCJ acts with TopBP1 and participates early in DNA replication checkpoint control. Mol Cell 37(3):438–446
Gorgoulis VG et al (2005) Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434(7035):907–913
Gottlieb TM, Jackson SP (1993) The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen. Cell 72(1):131–142
Graham TG, Walter JC, Loparo JJ (2016) Two-stage synapsis of DNA ends during non-homologous end joining. Mol Cell 61(6):850–858
Gumy-Pause F, Wacker P, Sappino AP (2004) ATM gene and lymphoid malignancies. Leukemia 18(2):238–242
Gurley KE, Kemp CJ (2001) Synthetic lethality between mutation in Atm and DNA-PK(cs) during murine embryogenesis. Curr Biol 11(3):191–194
Halazonetis TD, Gorgoulis VG, Bartek J (2008) An oncogene-induced DNA damage model for cancer development. Science 319(5868):1352–1355
Harper JW et al (1995) Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6(4):387–400
Hollstein M et al (1991) p53 mutations in human cancers. Science 253(5015):49–53
Hurley LH (2002) DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer 2(3):188–200
Ishiai M et al (2008) FANCI phosphorylation functions as a molecular switch to turn on the Fanconi anemia pathway. Nat Struct Mol Biol 15(11):1138–1146
Kakarougkas A, Jeggo PA (2014) DNA DSB repair pathway choice: an orchestrated handover mechanism. Br J Radiol 87(1035):20130685
Kastan MB, Bartek J (2004) Cell-cycle checkpoints and cancer. Nature 432(7015):316–323
Kim H et al (2016) Targeting the ATR/CHK1 Axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian cancer models. Clin Cancer Res 23(12):3097–3108
Kiraz Y et al (2016) Major apoptotic mechanisms and genes involved in apoptosis. Tumour Biol 37(7):8471–8486
Kolas NK et al (2007) Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. Science 318(5856):1637–1640
Krajewska M et al (2015) ATR inhibition preferentially targets homologous recombination-deficient tumor cells. Oncogene 34(26):3474–3481
Kwak EL et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693–1703
Lavin MF (2007) ATM and the Mre11 complex combine to recognize and signal DNA double-strand breaks. Oncogene 26(56):7749–7758
Lee J, Kumagai A, Dunphy WG (2001) Positive regulation of Wee1 by Chk1 and 14-3-3 proteins. Mol Biol Cell 12(3):551–563
Leung M et al (2011) Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality. Mol Med 17(7–8):854–862
Li J, Stern DF (2005) Regulation of CHK2 by DNA-dependent protein kinase. J Biol Chem 280(12):12041–12050
Litman R et al (2005) BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 8(3):255–265
Liu Q et al (2000) Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 14(12):1448–1459
Lord CJ, Ashworth A (2016) BRCAness revisited. Nat Rev Cancer 16(2):110–120
Ma Y et al (2002) Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell 108(6):781–794
Mailand N et al (2000) Rapid destruction of human Cdc25A in response to DNA damage. Science 288(5470):1425–1429
Mailand N et al (2007) RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell 131(5):887–900
Malkin D et al (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250(4985):1233–1238
Malone KE et al (2006) Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res 66(16):8297–8308
Marsit CJ et al (2004) Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 23(4):1000–1004
Matos J, West SC (2014) Holliday junction resolution: regulation in space and time. DNA Repair (Amst) 19:176–181
Matsuoka S et al (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316(5828):1160–1166
Mazin AV et al (2010) Rad54, the motor of homologous recombination. DNA Repair (Amst) 9(3):286–302
Mendes-Pereira AM et al (2009) Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 1(6–7):315–322
Merrick CJ, Jackson D, Diffley JF (2004) Visualization of altered replication dynamics after DNA damage in human cells. J Biol Chem 279(19):20067–20075
Mohni KN et al (2015) A synthetic lethal screen identifies DNA repair pathways that sensitize cancer cells to combined ATR inhibition and cisplatin treatments. PLoS One 10(5):e0125482
Mueller PR et al (1995) Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science 270(5233):86–90
Murai J et al (2012) Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res 72(21):5588–5599
Murga M et al (2011) Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol 18(12):1331–1335
NIH 2015 National cancer institite–side effects. 04/29/15 [cited 2016 11/14/16]; Available from: https://www.cancer.gov/about-cancer/treatment/side-effects
Nilsson JA, Cleveland JL (2003) Myc pathways provoking cell suicide and cancer. Oncogene 22(56):9007–9021
Norbury C, Blow J, Nurse P (1991) Regulatory phosphorylation of the p34cdc2 protein kinase in vertebrates. EMBO J 10(11):3321–3329
Parker LL, Piwnica-Worms H (1992) Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 257(5078):1955–1957
Patel AG, Sarkaria JN, Kaufmann SH (2011) Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A 108(8):3406–3411
Prevo R et al (2012) The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Cancer Biol Ther 13(11):1072–1081
Ragland RL et al (2013) RNF4 and PLK1 are required for replication fork collapse in ATR-deficient cells. Genes Dev 27(20):2259–2273
Reaper PM et al (2011) Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol 7(7):428–430
Regal JA et al (2013) Disease-associated MRE11 mutants impact ATM/ATR DNA damage signaling by distinct mechanisms. Hum Mol Genet 22(25):5146–5159
Riabinska A et al (2013) Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. Sci Transl Med 5(189):189ra78
Rogakou EP et al (1998) DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273(10):5858–5868
Santocanale C, Diffley JF (1998) A Mec1- and Rad53-dependent checkpoint controls late-firing origins of DNA replication. Nature 395(6702):615–618
Schoppy DW et al (2012) Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR. J Clin Invest 122(1):241–252
Shiloh Y, Ziv Y (2013) The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol 14(4):197–210
Siddick ZH (2002) The cancer handbook. In: Mechanisms of action of cancerchemotherapeutic agents: DNA-interactive alkylating agents and antitumour platinum-based drugs, 1st edn. John Wiley & Sons, Ltd, Hoboken, New Jersey
Sorensen CS et al (2003) Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell 3(3):247–258
Sorensen CS et al (2005) The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 7(2):195–201
Sosman JA et al (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366(8):707–714
Stewart GS et al (2003) MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature 421(6926):961–966
Stiff T et al (2004) ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res 64(7):2390–2396
Strausfeld U et al (1991) Dephosphorylation and activation of a p34cdc2/cyclin B complex in vitro by human CDC25 protein. Nature 351(6323):242–245
Sy SM, Huen MS, Chen J (2009) PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci U S A 106(17):7155–7160
Toledo LI et al (2011) A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat Struct Mol Biol 18(6):721–727
Toledo LI et al (2013) ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell 155(5):1088–1103
Turner N, Tutt A, Ashworth A (2004) Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 4(10):814–819
Varon R et al (2001) Mutations in the nijmegen breakage syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL). Cancer Res 61(9):3570–3572
Vita M, Henriksson M (2006) The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 16(4):318–330
Waddell N et al (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518(7540):495–501
Waters LS et al (2009) Eukaryotic translesion polymerases and their roles and regulation in DNA damage tolerance. Microbiol Mol Biol Rev 73(1):134–154
Welburn JP et al (2007) How tyrosine 15 phosphorylation inhibits the activity of cyclin-dependent kinase 2-cyclin A. J Biol Chem 282(5):3173–3181
Williams JS, Lujan SA, Kunkel TA (2016) Processing ribonucleotides incorporated during eukaryotic DNA replication. Nat Rev Mol Cell Biol 17(6):350–363
Wyatt HD et al (2013) Coordinated actions of SLX1-SLX4 and MUS81-EME1 for Holliday junction resolution in human cells. Mol Cell 52(2):234–247
Xia B et al (2006) Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell 22(6):719–729
Yazinski SA et al (2017) ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev 31(3):318–332
Zamborszky J et al (2017) Loss of BRCA1 or BRCA2 markedly increases the rate of base substitution mutagenesis and has distinct effects on genomic deletions. Oncogene 36(6):746–755
Zeman MK, Cimprich KA (2014) Causes and consequences of replication stress. Nat Cell Biol 16(1):2–9
Zhao H, Watkins JL, Piwnica-Worms H (2002) Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci U S A 99(23):14795–14800
Zou L, Elledge SJ (2003) Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 300(5625):1542–1548
Acknowledgments
We would like to thank our support from the National Cancer Institute of the National Institutes of Health under award numbers: R41CA203436 (LB, OG, EJB) and 1R01CA189743 (EJB). Additional funding was provided through the Ben Franklin Technology Partners of Southeastern PA, an initiative of the Pennsylvania Department of Community and Economic Development funded by the Ben Franklin Technology Development Authority (LB, OG), the Pennsylvania Department of Health (EJB), The Basser Center for BRCA Research (EJB), and the Abramson Family Cancer Research Institute (EJB).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Butler, L.R., Gilad, O., Brown, E.J. (2018). The DNA Damage Response: Roles in Cancer Etiology and Treatment. In: Pollard, J., Curtin, N. (eds) Targeting the DNA Damage Response for Anti-Cancer Therapy. Cancer Drug Discovery and Development. Humana Press, Cham. https://doi.org/10.1007/978-3-319-75836-7_2
Download citation
DOI: https://doi.org/10.1007/978-3-319-75836-7_2
Published:
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-75834-3
Online ISBN: 978-3-319-75836-7
eBook Packages: MedicineMedicine (R0)